Our Business Divisions
We operate through the following divisional companies:
ValiPharma is a biopharmaceutical company focused on developing personalised medicines to bring more advanced therapeutic options for the treatment of cancer. For many years the Company has progressively exploited its proprietary epigenomic technology, which has led to the discovery of promising therapeutics that may in clinical trials prove effective in combating cancer safely and more effectively than currently used chemotherapeutics, which act indiscriminately, attacking the whole body and causing irreparable damage to normal cellular processes.
Currently, ValiPharma has a lead drug candidate, VAL201, in a Phase I/II clinical trial for two indications – androgen independent prostate cancer and hormone refractory prostate cancer. Review of the pre-clinical data obtained with VAL201 has also revealed a third indication, which has been named VAL301. VAL301 is currently in pre-clinical development, for the major gynecological condition, Endometriosis.
ValiSeek is ValiRx’s joint venture company with Tangent Reprofiling Limited, which was formed in 2014 to progress the drug, VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications. VAL401 is a reformulated drug with an established safety record derived from clinical studies and years of use in other medical areas. VAL401 entered the clinic having demonstrated encouraging pre-clinical data as far as lung, prostate and pancreatic tumours were concerned. ValiRx subsidiary, ValiSeek, has now completed its clinical Phase II trials in Tbilisi, Georgia on subjects with advanced non-small cell lung cancer and data from the completed trial indicates a palliative effect and an improvement of quality of life in the patients treated. ValiSeek is currently in discussions with potential partners for starting the next clinical trial.